JAC Advance Access published online on September 13, 2007
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkm310
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Antimicrobial susceptibility among organisms from the Asia/Pacific Rim, Europe and Latin and North America collected as part of TEST and the in vitro activity of tigecycline
1 Institute for Medical Microbiology, National Reference Centre for Streptococci, Aachen, Germany 2 Department of Microbiology, Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada 3 Microbiology Laboratory, Hospital das Clinicas da Faculdade de Medicina, São Paulo, Brazil 4 Peking Union Medical College Hospital, Beijing, China 5 Department of Microbiology, Sir Gangaram Hospital, New Delhi, India 6 Infectious Disease Group, Wyeth Pharmaceuticals, Collegeville, PA, USA
Received 25 April 2007; returned 1 June 2007; revised 6 July 2007; accepted 27 July 2007
* Corresponding author. Tel: +49-241-8089946; Fax: +49-241-8082483; E-mail: reinert{at}rwth-aachen.de
Objectives: To describe antimicrobial susceptibility among bacterial isolates associated with hospital infections collected from 266 centres in Asia/Pacific Rim (n = 1947), North America (n = 24 283), Latin America (n = 1957) and Europe (n = 8796).
Methods: Isolates were collected from blood, respiratory tract, urine, skin, wound, body fluids and other defined sources between January 2004 and August 2006. Only one isolate per patient was accepted. In vitro MICs for the isolates were determined according to the CLSI (formerly NCCLS) guidelines.
Results: Key organisms collected were Acinetobacter baumannii (n = 2902), Enterobacter spp. (n = 5731), Escherichia coli (n = 6504), Klebsiella pneumoniae (n = 4916), Pseudomonas aeruginosa (n = 5128), Serratia marcescens (n = 2313), Enterococcus faecalis (n = 2701), Enterococcus faecium (n = 1035) and Staphylococcus aureus (n = 5753). Rates of methicillin resistance among S. aureus and of vancomycin resistance among enterococci were highest in North America (2016/3809, 52.9% and 571/2544, 22.4%, respectively) and lowest in Europe (337/1340, 25.1% and 36/916, 3.9%, respectively). Tigecycline was the only antimicrobial to maintain activity against all Gram-positive isolates (MIC90 values of 
0.25 mg/L). Overall, tigecycline and imipenem were the most active (>93% susceptibility in all regions) antimicrobials against the Gram-negative species, except for A. baumannii and P. aeruginosa. Piperacillin/tazobactam and amikacin were the most active against P. aeruginosa. Extended-spectrum ß-lactamase producers among K. pneumoniae occurred most frequently in Latin America (124/282, 44.0%).
Conclusions: Tigecycline is a novel broad-spectrum antimicrobial that is active against the common organisms associated with infections.
Key Words: global , hospital infections , surveillance , resistance
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. L. Crandon, M. A. Banevicius, and D. P. Nicolau Pharmacodynamics of Tigecycline against Phenotypically Diverse Staphylococcus aureus Isolates in a Murine Thigh Model Antimicrob. Agents Chemother., March 1, 2009; 53(3): 1165 - 1169. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Grim, I. Hong, J. Freeman, C. Edwards, and N. M. Clark Daptomycin for the treatment of vancomycin-resistant enterococcal infections J. Antimicrob. Chemother., February 1, 2009; 63(2): 414 - 416. [Full Text] [PDF]
|
|
|
|
|
|
T. Kelesidis, D. E. Karageorgopoulos, I. Kelesidis, and M. E. Falagas Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies J. Antimicrob. Chemother., November 1, 2008; 62(5): 895 - 904. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M. Hawkey The growing burden of antimicrobial resistance J. Antimicrob. Chemother., September 1, 2008; 62(suppl_1): i1 - i9. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C Gallagher and H. M Rouse Tigecycline for the Treatment of Acinetobacter Infections: A Case Series Ann. Pharmacother., September 1, 2008; 42(9): 1188 - 1194. [Abstract] [Full Text] [PDF]
|
|